Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) insider Michael Vasconcelles sold 2,728 shares of the company's stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total transaction of $31,644.80. Following the completion of the sale, the insider directly owned 4,397 shares of the company's stock, valued at $51,005.20. The trade was a 38.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Day One Biopharmaceuticals Stock Down 2.7%
Day One Biopharmaceuticals stock opened at $11.56 on Thursday. Day One Biopharmaceuticals, Inc. has a 52 week low of $5.64 and a 52 week high of $13.20. The company's 50 day moving average price is $10.34 and its two-hundred day moving average price is $8.57. The stock has a market cap of $1.19 billion, a P/E ratio of -7.61 and a beta of -1.26.
Hedge Funds Weigh In On Day One Biopharmaceuticals
Several large investors have recently modified their holdings of DAWN. Vanguard Group Inc. lifted its stake in shares of Day One Biopharmaceuticals by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 6,282,376 shares of the company's stock valued at $58,552,000 after buying an additional 101,047 shares in the last quarter. Vestal Point Capital LP raised its holdings in Day One Biopharmaceuticals by 94.4% during the 4th quarter. Vestal Point Capital LP now owns 5,200,000 shares of the company's stock valued at $48,464,000 after acquiring an additional 2,525,000 shares during the period. Deerfield Management Company L.P. raised its holdings in Day One Biopharmaceuticals by 26.4% during the 3rd quarter. Deerfield Management Company L.P. now owns 4,705,413 shares of the company's stock valued at $33,173,000 after acquiring an additional 982,282 shares during the period. State Street Corp lifted its position in shares of Day One Biopharmaceuticals by 32.4% during the fourth quarter. State Street Corp now owns 4,289,566 shares of the company's stock worth $39,979,000 after acquiring an additional 1,049,122 shares in the last quarter. Finally, Franklin Resources Inc. boosted its holdings in shares of Day One Biopharmaceuticals by 2.0% in the second quarter. Franklin Resources Inc. now owns 4,097,625 shares of the company's stock worth $26,635,000 after acquiring an additional 79,255 shares during the period. Hedge funds and other institutional investors own 87.95% of the company's stock.
Key Headlines Impacting Day One Biopharmaceuticals
Here are the key news stories impacting Day One Biopharmaceuticals this week:
- Positive Sentiment: Wall Street support remains: several firms previously raised price targets or maintained buy/overweight views (Piper Sandler, JPMorgan, Needham, HC Wainwright), which provides longer‑term tailwinds for the name. MarketBeat analyst summary
- Neutral Sentiment: Reported short interest data looks anomalous (effectively zero as of Feb. 17) and appears to contain reporting errors — this offers no clear directional signal and should be treated with caution. MarketBeat short interest note
- Negative Sentiment: Clustered insider selling by senior management on Feb. 17 likely pressured sentiment: CEO Jeremy Bender sold 15,459 shares, CFO Charles N. York II sold 6,065 shares and other insiders (Adam Dubow, Lauren Merendino, Michael Vasconcelles) sold additional stakes — roughly 36,500 shares in aggregate at about $11.60 each (~$423k). Such coordinated reductions by executives can be read negatively by the market. CEO Form 4 InsiderTrades summary
- Negative Sentiment: Zacks preview warns Day One may lack the setup for an earnings beat in the upcoming report, signaling the risk of a negative surprise that can further weigh on near‑term trading. Zacks preview
Analyst Upgrades and Downgrades
DAWN has been the subject of a number of recent analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of Day One Biopharmaceuticals in a research note on Monday, December 29th. HC Wainwright reissued a "buy" rating and issued a $25.00 price target on shares of Day One Biopharmaceuticals in a report on Monday, November 24th. Needham & Company LLC restated a "buy" rating and set a $16.00 price objective on shares of Day One Biopharmaceuticals in a report on Monday, November 24th. Zacks Research upgraded shares of Day One Biopharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Monday, January 26th. Finally, TD Cowen initiated coverage on shares of Day One Biopharmaceuticals in a research note on Tuesday, January 13th. They set a "buy" rating and a $34.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $25.71.
Check Out Our Latest Report on Day One Biopharmaceuticals
Day One Biopharmaceuticals Company Profile
(
Get Free Report)
Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.
The company's pipeline includes several small-molecule candidates in various stages of development.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
